John Sulston, who coordinated the UK side of the international publicly funded efforts to sequence 'the' human genome, once said the endeavour was like a moon shot. He may only have referred to the scale and ambition of the project, but one could argue that, in both cases, outdated technology and extraordinary amounts of money were used to hit a highly visible and prestigious target, just to show that one can do it. In both cases, the benefits remained rather limited. While the moon landings turned into a picturesque blind alley of human exploration, the really useful work in human genomics only started after the first human genome was mostly complete.
Like the moon landings, the human genome project used technology that had essentially been available for decades. In this case, it was the chain termination sequencing method, which Frederick Sanger developed around 1975, and which earned him his second Nobel Prize in 1980. It was made more efficient later when the read-out of radioactive labels from a slab gel was replaced by fluorescence marking (with different colours indicating As, Cs, Gs and Ts) and capillary electrophoresis.
Sanger's principle, however, remained in place, and its Achilles' heel is the fact that every single position of the sequence to be read has to be represented by a population of DNA molecules that ends with this position. Hence, the amount of DNA required is much larger than the minimal number of molecules that can be detected by the read-out technique. The theoretical minimum is the detection limit times half the length of the sequence to be determined in one run (which is the average length of the fragments if you have equal numbers of fragments ending at each position).
This principle, while tolerable in small sequencing projects, is what made the human genome project astronomically expensive. If sequencing genomes were ever to become useful, one had to get out of the chain termination principle. And ideally one would also want to achieve what cells have been doing for billions of years, namely read individual DNA molecules rather than populations of thousands.
The second generation
As the human genome juggernaut approached the final stages of the project, only slightly spurred on by the competition from Craig Venter's private effort, which also relied on Sanger sequencing, researchers were already thinking about the next generation that would not terminate and discard a population of DNA chains for every base read.
In 2005, just two years after the official completion of the human genome project, the first of the 'next generation' sequencing machines reached the market. Within two years, several companies introduced new techniques, all of which managed to avoid the fundamental problem with chain termination in different ways.
The current market leader, Illumina, uses the Solexa technique, which is based on fluorescent labels and chain termination, just like its predecessors. The clever trick, however, is that a chemical modification to the chain-terminating nucleotides makes the termination reversible. After the Only six years after 'next generation' sequencing sent the cost of a human genome spiralling downwards, a third generation now promises single molecule read-out and electronic detection. Michael Gross reports. base has been identified, the block can be removed, and the next base can be attached.
Genomics in permanent revolution
In the pyrophosphate technique in the instruments from the company 454, which have sequenced the genomes of James Watson and a nameless Neanderthal, the pyrophosphate cleaved off during the chain elongation reaction provides a signal that a nucleotide has been attached, so there is no chain termination involved.
Applied Biosystems, a market leader in the times of Sanger sequencing, uses the SOLiD technology, which constructs a complementary strand from short labelled oligonucleotides.
Between them, these 'next generation' techniques have succeeded in driving down the cost of a human genome by five orders of magnitude, from around a billion dollars to tens of thousands of dollars, and have enabled the advent of personal genomics, i.e. the sequencing of many individual human genomes. Major sequencing centres like the Wellcome Trust Sanger Centre at Hinxton near Cambridge and the BGI at Shenzhen, China, have more than 100 second generation instruments, enabling them to read the equivalent of dozens of human genomes per day. However, there is still room for improvement both in the amount of DNA needed for a sequencing run, and in the bulk of equipment required for the process.
The third generation
When the cell transcribes and translates genetic information, it always starts from a single molecule of DNA, which is read out by molecular machines at breathtaking speed. So why can't we build machines that achieve the same?
Recent years have seen increasing efforts to bring down read-out sensitivity to the single-molecule level. The first commercial instrument to achieve this is the heliscope produced by the company Helicos Biosciences. In 2009, Helicos co-founder Stephen Quake published the sequence of his own genome, the first human genome to be analysed by single-molecule techniques. Last year, Quake went one step further and published a full medical analysis of the information extracted from his genome (The Lancet (2010 ), 375, 1525 -1535 .
Like the now ubiquitous Solexa technique, the Helicos instrument monitors the synthesis of new DNA using fluorescence detection. The DNA strands are anchored on a microchip and offered nucleotides for chain extension one sort at a time. After each reaction, the machine takes a photo of the chip, with a bright spot identifying each chain that has had a successful chain extension reaction with the nucleotide that has been offered.
This method won the race to be the first single-molecule sequencer on the market, and the sequencing of Quake's genome with minimal manpower and consumables cost clearly demonstrated its usefulness. Its weakness, however, is the optical detection of the chain extension, which depends on the precise location of each DNA strand in the microphotograph. This requires a vibration-free set-up, i.e. a large granite table in a suitable building. It makes the instrument significantly more expensive than the ones currently in use, and rules out any thoughts of widespread use in medical practices.
Last December, Life Technologiesthe company resulting from the merger of Applied Biosystems and Invitrogenat Carlsbad, California, launched the Ion Personal Genomics Machine developed by the start-up company Ion Torrent, which Life Technologies had bought up just months earlier. Ion Torrent is the brainchild of Jonathan Rothberg, who also developed the 454 technology.
While it doesn't achieve singlemolecule resolution, the Ion Torrent technology has an advantage that the Helicos approach lacks in that it uses electronic detection. It is based on a novel approach, namely the detection of hydrogen ions released during the nucleotide coupling. Thus, the machine is essentially a highly sophisticated pH meter. In each reaction step, one of the four nucleotides is offered for chain extension, and from the amplitude of the signal produced by the protons released, one can conclude whether one or several copies of the specific nucleotide were appended to the growing chain. As electronic detection is much simpler than optical methods, the resulting instrument is a userfriendly and relatively affordable desktop box that could be installed anywhere.
The company Pacific Biosciences (PacBio) at Menlo Park, California announced at the end of April that, following a limited trial phase with selected institutions, it is now shipping its new sequencer on a fullscale commercial base. A prototype has already served in identifying the origin of the cholera germs during the recent outbreak in Haiti (N. Engl. J. Med. (2011), 364, 33-42).
The Wellcome Trust Sanger Centre already has one PacBio RS alongside two Ion Torrent machines, with the aim to explore the new technologies. A spokesman said: "Although they will initially be used as a research platform, our experience with these devices will give us insight into the direction that DNA sequencing technology will go and allow us to develop plans to support and exploit it."
PacBio uses synthesis-based sequencing and fluorescence detection like most of the existing instruments, but has managed to scale down the reaction vessel to the extent that only one DNA molecule can fit in.
The key component is a trough measuring only tens of nanometres across. As this is much below the wavelength of visible light, the trough acts as a zero mode waveguide (ZMW), allowing light only to penetrate some 20-30 nanometres into the space, which means that the volume accessible to the light is as small as 20 zeptolitres (10 -21 litres). On a larger scale, the same phenomenon is used in the perforated screens in the doors of microwave ovens. As microwaves have much longer wavelengths than visible light, the holes that are impenetrable to them are transparent for visible light.
If a DNA polymerase operates within this very small volume, replicating a single DNA strand, there is no space for other molecules that might contribute any noise. Thus, any fluorescence signal coming back from this cavity is bound to be a relevant signal indicating the extension of the chain with a nucleotide. To be quite sure that there is no unwanted fluorescence, PacBio have attached the fluorescence label to the pyrophosphate that is cleaved off during the coupling reaction, meaning that the growing chain doesn't fluoresce.
Another company that has been developing new technologies in recent years is Complete Genomics, based in Mountain View, California. However, this company does not aim to sell instruments. Instead it only builds them for its own use in commercial DNA sequencing. Thus, the company doesn't divulge too much information about their technology. Their key innovation appears to be in the way of immobilising DNA strands using 'DNA nanoballs'. The materials cost quoted by Complete Genomics for a personal genome has been comparable if not lower than that obtained with other instruments, suggesting that the technology is on the same level as those of the companies developing commercial instruments.
Towards the perfect genome sequencer So far, each of the new instruments has fulfilled some but not all of the hopes attached to the coming of the third generation. The Heliscope and Pacific Biosciences RS have achieved single-molecule sequencing, and Ion Torrent has electronic detection. But can these improvements be achieved in the same instrument, and can this instrument be compact, affordable, and user-friendly?
Up to now, it is far from clear which of the competing companies may win the race to the perfect third generation machine, the one that may turn up on the desk of your family doctor at some point in the future.
Oxford Nanopore Technologies is aiming for no less than the complete package: single-molecule, electronic, compact, scalable, affordable, and user-friendly. Originally spun out of the laboratory of Hagan Bayley at the University of Oxford, Oxford Nanopore now has collaborations with Harvard, the University of California at Santa Clara (UCSC) and other institutions.
Oxford Nanopore is exploring two methods of DNA sequencing with biological nanopores: exonuclease sequencing (for which the company has a commercialisation agreement with Illumina) and strand sequencing. A team at the company led by Chief Scientific Officer John Milton, who also developed the Solexa technique, has made adaptations to biological nanopores so that they can be used to identify DNA bases in sequence. Nanopore sequencing uses a potential difference across the membrane to drive DNA through the pore as individual nucleotides or an intact strand.
A previous publication from Oxford Nanopore has shown individual identification of each of the four DNA nucleotides, as each affects the current across the membrane in a characteristic way. In addition, the set-up can also identify the methylated cytosine, which is important for epigenetic research. In both the exonuclease and strand methods a processive enzyme manipulates the DNA to pass it through the nanopore; recent research in this area includes that of Mark Akeson's UCSC laboratory which showed that the enzyme phi29 can ratchet singlestranded DNA through a nanopore. Apart from this work with biological nanopores, Oxford Nanopore also has an interest in solid-state nanopores and has recently signed a licence agreement with Harvard University covering the development of graphene nanopores.
Another intriguing approach has been explored by the company VisiGen Biotechnologies, which is now also part of Life Technologies. VisiGen researchers have coupled the DNA polymerase with a quantum dot, whose optical properties are so sensitive to the molecular environment that it can distinguish which of the four nucleotides has just docked to the polymerase. However, it is not clear yet whether the technique can distinguish between productive encounters that lead to chain extension and non-productive ones, in which a non-matching nucleotide is checked and then discarded.
Pore progress: Oxford Nanopore's modified nanopore can distinguish between the four standard DNA nucleotides and methylated cytosine. The aim is to use an endonuclease (green) to feed the nucleotides to the pore one by one. (Photo: iemedia solutions.)
Coming soon to a doctor's surgery near you? Hopes placed on the sequencing of 'the' human genome and the subsequent identification of many single-nucleotide polymorphisms (SNPs) have turned out to be misguided, as the causes of common diseases like cancer and heart disease have proven too complex to be addressed with simple SNP searches. Also, large-scale genomic differences like copy number variations (CNV) and insertions/deletions (indels) are now known to be equally important as SNPs, rendering the quest for genomic answers to medical problems ever more challenging.
There is, however, the hope that large-scale analysis of individual genomes may yield some of the answers that SNPs failed to provide. And the rapid progress in sequencing technology, with the costs dropping more rapidly than those of computer technology (still following Moore's Law), means that comparing thousands of individual genomes, thoughtfully chosen by epidemiological criteria, is now a perfectly viable approach to medical genomics.
At the more individual level, affordable genome analysis is also bound to aid diagnosis and therapy, especially in cancer. Soon it will be easy to compare the genome of a tumour with that of the patient's healthy cells, enabling doctors to find out both what went wrong and what treatment is most likely to succeed. And this, when it happens, will be the real genome revolution.
